FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150948737> ?p ?o ?g. }

• W2150948737 abstract "Abstract Background Osteosarcoma (OS) is the most common primary bone malignancy with a high propensity for local invasion and distant metastasis. Limited by the severe toxicity of conventional agents, the therapeutic bottleneck of osteosarcoma still remains unconquered. Flavokawain B (FKB), a kava extract, has been reported to have significant anti-tumor effects on several carcinoma cell lines both in vitro and in vivo . Its efficacy and low toxicity profile make FKB a promising agent for use as a novel chemotherapeutic agent. Results In the current study, we investigated the anti-proliferative and apoptotic effects of FKB against human osteosarcomas. Exposure of OS cells to FKB resulted in apoptosis, evidenced by loss of cell viability, morphological changes and the externalization of phosphatidylserine. Apoptosis induced by FKB resulted in activation of Caspase-3/7, -8 and −9 in OS cell lines, 143B and Saos-2. FKB also down-regulated inhibitory apoptotic markers, including Bcl-2 and Survivin and led to concomitant increases in apoptotic proteins, Bax, Puma and Fas. Therefore, the induction of apoptosis by FKB involved both extrinsic and intrinsic pathways. FKB also caused G2/M phase cell cycle arrest, which was observed through reductions in the levels of cyclin B1, cdc2 and cdc25c and increases in Myt1 levels. Furthermore, migration and invasion ability was decreased by FKB in a dose-dependent manner. The cytotoxicity profile showed FKB had significant lower side effects on bone marrow cells and small intestinal epithelial cells compared with Adriamycin. Conclusions Taken together, our evidence of apoptosis and cell cycle arrest by FKB treatment with less toxicity than the standard treatments provides an innovative argument for the use of FKB as a chemotherapeutic and chemopreventive compound. In vivo experiments utilizing FKB to reduce tumorigenesis and metastatic potential will be crucial to further justify clinical application." @default.
• W2150948737 created "2016-06-24" @default.
• W2150948737 creator A5019096929 @default.
• W2150948737 creator A5024822525 @default.
• W2150948737 creator A5033980726 @default.
• W2150948737 creator A5036496290 @default.
• W2150948737 creator A5049178289 @default.
• W2150948737 creator A5073985851 @default.
• W2150948737 creator A5077636119 @default.
• W2150948737 date "2013-06-10" @default.
• W2150948737 modified "2023-10-13" @default.
• W2150948737 title "Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis" @default.
• W2150948737 cites W1552375166 @default.
• W2150948737 cites W1967880683 @default.
• W2150948737 cites W1977233265 @default.
• W2150948737 cites W1984483611 @default.
• W2150948737 cites W1992018116 @default.
• W2150948737 cites W1996850609 @default.
• W2150948737 cites W1999901442 @default.
• W2150948737 cites W2008715871 @default.
• W2150948737 cites W2011909871 @default.
• W2150948737 cites W2018795692 @default.
• W2150948737 cites W2049426872 @default.
• W2150948737 cites W2050810651 @default.
• W2150948737 cites W2055171457 @default.
• W2150948737 cites W2056976274 @default.
• W2150948737 cites W2071282309 @default.
• W2150948737 cites W2081737065 @default.
• W2150948737 cites W2087032376 @default.
• W2150948737 cites W2092756278 @default.
• W2150948737 cites W2097241191 @default.
• W2150948737 cites W2099029525 @default.
• W2150948737 cites W2100592123 @default.
• W2150948737 cites W2118680832 @default.
• W2150948737 cites W2119800239 @default.
• W2150948737 cites W2120585583 @default.
• W2150948737 cites W2136399690 @default.
• W2150948737 cites W2141474275 @default.
• W2150948737 cites W2156430804 @default.
• W2150948737 cites W2160980887 @default.
• W2150948737 cites W2163542519 @default.
• W2150948737 cites W2165411440 @default.
• W2150948737 cites W2169942411 @default.
• W2150948737 cites W42123934 @default.
• W2150948737 doi "https://doi.org/10.1186/1476-4598-12-55" @default.
• W2150948737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3681603" @default.
• W2150948737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23764122" @default.
• W2150948737 hasPublicationYear "2013" @default.
• W2150948737 type Work @default.
• W2150948737 sameAs 2150948737 @default.
• W2150948737 citedByCount "66" @default.
• W2150948737 countsByYear W21509487372013 @default.
• W2150948737 countsByYear W21509487372014 @default.
• W2150948737 countsByYear W21509487372015 @default.
• W2150948737 countsByYear W21509487372016 @default.
• W2150948737 countsByYear W21509487372017 @default.
• W2150948737 countsByYear W21509487372018 @default.
• W2150948737 countsByYear W21509487372019 @default.
• W2150948737 countsByYear W21509487372020 @default.
• W2150948737 countsByYear W21509487372021 @default.
• W2150948737 countsByYear W21509487372022 @default.
• W2150948737 countsByYear W21509487372023 @default.
• W2150948737 crossrefType "journal-article" @default.
• W2150948737 hasAuthorship W2150948737A5019096929 @default.
• W2150948737 hasAuthorship W2150948737A5024822525 @default.
• W2150948737 hasAuthorship W2150948737A5033980726 @default.
• W2150948737 hasAuthorship W2150948737A5036496290 @default.
• W2150948737 hasAuthorship W2150948737A5049178289 @default.
• W2150948737 hasAuthorship W2150948737A5073985851 @default.
• W2150948737 hasAuthorship W2150948737A5077636119 @default.
• W2150948737 hasBestOaLocation W21509487371 @default.
• W2150948737 hasConcept C105696609 @default.
• W2150948737 hasConcept C120504264 @default.
• W2150948737 hasConcept C190283241 @default.
• W2150948737 hasConcept C2775975398 @default.
• W2150948737 hasConcept C2777760704 @default.
• W2150948737 hasConcept C2779707156 @default.
• W2150948737 hasConcept C29537977 @default.
• W2150948737 hasConcept C502942594 @default.
• W2150948737 hasConcept C55493867 @default.
• W2150948737 hasConcept C62112901 @default.
• W2150948737 hasConcept C86803240 @default.
• W2150948737 hasConcept C95444343 @default.
• W2150948737 hasConceptScore W2150948737C105696609 @default.
• W2150948737 hasConceptScore W2150948737C120504264 @default.
• W2150948737 hasConceptScore W2150948737C190283241 @default.
• W2150948737 hasConceptScore W2150948737C2775975398 @default.
• W2150948737 hasConceptScore W2150948737C2777760704 @default.
• W2150948737 hasConceptScore W2150948737C2779707156 @default.
• W2150948737 hasConceptScore W2150948737C29537977 @default.
• W2150948737 hasConceptScore W2150948737C502942594 @default.
• W2150948737 hasConceptScore W2150948737C55493867 @default.
• W2150948737 hasConceptScore W2150948737C62112901 @default.
• W2150948737 hasConceptScore W2150948737C86803240 @default.
• W2150948737 hasConceptScore W2150948737C95444343 @default.
• W2150948737 hasIssue "1" @default.
• W2150948737 hasLocation W21509487371 @default.
• W2150948737 hasLocation W21509487372 @default.
• W2150948737 hasLocation W21509487373 @default.
• W2150948737 hasLocation W21509487374 @default.

• next